Back to results
US 2026/0295046 A1Published application
Sonosensitization
AssigneeSonalaSense, Inc.
InventorStuart L. MARCUS
Life of this patent
Estimating the term…
Abstract
An improved method for MRI-guided sonosensitized focused ultrasound treatment of malignant tissue is disclosed herein.
Claims37
A method for selectively inducing a directly cytotoxic effect or apoptosis within malignant tissue in a subject, the method comprising:
- a) providing an effective amount of 5-aminolevulinic acid, or a pharmaceutically acceptable salt or ester thereof, to the malignant tissue;
- and
- b) exposing the tissue to ultrasound energy (“sonicating”) using a focused ultrasound device, at a frequency of about 0.1 MHz to about 3 MHz, at an intensity at the ultrasound beam focus of about 3 W/cm2 to about 100 W/cm2.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-23. (canceled)
-29. (canceled)
-33. (canceled)
-44. (canceled)
(canceled)
(canceled)
(canceled)
A dosage form for use with a FUS device in the treatment of a subject in need of treatment, the dosage form comprising:
- a. a container, comprising an effective amount of 5-aminolevulinic acid sufficient to treat the subject;
- and
- b. a machine-readable identifier readable by the FUS device, wherein the machine-readable identifier identifies the source of the 5-aminolevulinic acid, the amount of 5-aminolevulinic acid, the subject for which the 5-aminolevulinic acid has been prescribed, the FUS treatment parameters prescribed for the subject, an identification code or serial number, or a combination thereof.
(canceled)
A system for treating malignant tissue in a subject, the system comprising:
- a. an effective amount of 5-aminolevulinic acid;
- and
- b. a focused ultrasound (FUS) device.
-59. (canceled)
Dependencies are inferred from the claim text.